SAUDI ARABIA – Global biotechnology company Horizon Therapeutics has inaugurated a new Technical Scientific Office (TSO) in the Kingdom of Saudi Arabia, solidifying its foothold the in the Middle East.

This strategic move will allow Horizon Therapeutics to extend its capacity and human reach to solve complex medical problems around the world with its new offices in Dublin, and now Riyadh.

In an official note, Horizon Therapeutics said: “Riyadh will be the home of our first Technical Scientific Office in the Middle East.”

The Ireland-born biotech company focuses on the discovery, development, and commercialization of medicines that address the critical needs of people impacted by rare, autoimmune and severe inflammatory diseases.

The opening of the new TSO in Riyadh reiterates the company’s commitment to transforming the lives of people living with rare, autoimmune, and severe inflammatory diseases across the world.

The Riyadh-based office will continue Horizon Therapeutics’ work to apply scientific expertise and courage to bring clinically meaningful therapies to patients.

“There is a significant unmet medical need in Saudi Arabia to provide healthcare solutions to patients living with rare, debilitating diseases,” said Fábio Ivankovich, Vice President of International Operations and General Manager of Horizon Therapeutics for the Latin America and Canada region.

“The opening of our TSO in Riyadh is the first step in enabling us to provide our medicines to meet the needs of rare disease patients,” Ivankovich reaffirmed to the doctors and patients in Saudi Arabia.

Similarly, international companies are expanding their network into the Middle East by setting up regional offices including the new Joint Commission International office in Riyadh while AstraZeneca plans to construct sustainable offices at Dubai Science Park.

The Alliance of Academic Health Centres International also formally designated the Mohammed bin Rashid University of Medicine and Health Sciences (MBRU) as its Regional Office for the Middle East and North Africa region (MENA).

This news comes as the Saudi sovereign Public Investment Fund’s (PIF) plans to empower the private sector, support real estate projects and local infrastructure, and diversify the economy’s sources of income.

Moreover, Horizon Therapeutics has tied up with Saudi Arabia-based Cigalah Healthcare Company to commence the operation of the new Middle East Technical Scientific Office in Riyadh.

The recent development will help to consolidate the position of the Kingdom of Saudi Arabia as a global gateway to medical biotechnology.

“We welcome Horizon Therapeutics as it opens its Middle East TSO in the heart of Riyadh, building upon Saudi Arabia’s advancements in the region’s growing biotechnology community,” stated Yasser Naghi, Chief Executive Officer (CEO) of Cigalah.

He noted that the strategic move builds on the momentum of the Saudi Vision 2030 plan to build international partnerships for medical biotechnology and create programs to develop the national pharmaceutical industry.

“In line with Vision 2030, our strategic partnership is set to transform the rare disease community in Saudi Arabia and provide patients with increased access to healthcare solutions,” asserted Naghi.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.